In China, Surveyed Nephrologists Report Significant Declines in the Use of
ESAs in Stage 3, 4 and 5 Chronic Kidney Disease Non-Dialysis Patient
Populations, Compared with 2011
After Review of Three Renal Anemia Product Profiles in Development, Expected
Use Increases with Disease Severity, According to Findings from Decision
BURLINGTON, Mass., July 1, 2014
BURLINGTON, Mass., July 1, 2014 /PRNewswire/ --Decision Resources Group finds
that patient chart data submitted by surveyed nephrologists in China reveals
that, consistent with 2011, the percentage of patients on
erythropoiesis-stimulating agents (ESAs) significantly increases as chronic
kidney disease (CKD) worsens; however, for stage 3, stage 4 and stage 5
non-dialysis (ND), the percentage of patients on ESAs has declined
significantly compared with 2011.
Decision Resources Group Logo.
Other key findings from the report entitled ChartTrends: Renal Anemia in
CKD-ND (China) 2014:
oESA-treated patient demographics: Patients treated with ESAs tend to be in
a later stage of CKD; tend to have more comorbidities and lower hemoglobin
levels; are more likely to be on traditional Chinese medicine for the
treatment of renal anemia; are more likely to be on iron (IV or oral),
phosphate binders, and active Vitamin D; and are of higher economic status
compared with ESA non-treated patients. (The report also includes patient
share data for Shenyang Sunshine Pharmaceutical's Yi Bi Ao, Kyowa Hakko
Kirin's ESPO, Hua Bae Pharm's Ji Main Xin and other agents.)
oOver-reporting of IV iron use in Stage 3: While surveyed nephrologists'
report that the percentage of CKD stage 4 patients on IV iron is
consistent with chart audited data, respondents appear to overestimate the
percentage of stage 3 patients who are treated with IV iron. (The report
also includes further details on IV iron patient share, discontinuation
rates, transferrin saturation and ferritin distributions at last measure
and at IV iron initiation, IV iron administration location, dosing,
switching and rationale for switching from oral to IV iron, among other
oExpected use of products in development: New to this study, nephrologists
reviewed product profiles of three products in late-stage development for
renal anemia. Then, nephrologists indicated whether a particular patient
would or would not be eligible for treatment with these products and why
or why not they would be eligible for treatment with these products. Among
those that would be eligible, nephrologists were asked whether a patient's
current ESA use would change. Products covered in the report include
FibroGen's/AstraZeneca's/Astellas's roxadustat, Akebia's AKB-6548 and
Keryx/Japan Tobacco's Zerenex/Riona. Not surprisingly, expected use
increases with stage of the disease.
Comments from Decision Resources Group Director Rob Dubman:
o"It is not surprising that information from patient charts show declines
in the use of ESAs because we have generally observed this trend in other
markets around the globe as well."
o"Adding product profiles to this study created some interesting findings.
For example, this physician exercise allows manufactures to see how
expected use differs by lab values and/or other patient demographics."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and
insights on critical issues within the healthcare industry. Clients rely on
this analysis and data to make informed decisions. Find out more at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group
Press spacebar to pause and continue. Press esc to stop.